These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33469552)

  • 1. Gender-Related Differences in Heart Failure Biomarkers.
    Cediel G; Codina P; Spitaleri G; Domingo M; Santiago-Vacas E; Lupón J; Bayes-Genis A
    Front Cardiovasc Med; 2020; 7():617705. PubMed ID: 33469552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-related differences in contemporary biomarkers for heart failure: a review.
    Suthahar N; Meems LMG; Ho JE; de Boer RA
    Eur J Heart Fail; 2020 May; 22(5):775-788. PubMed ID: 32220046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular biomarkers and sex: the case for women.
    Daniels LB; Maisel AS
    Nat Rev Cardiol; 2015 Oct; 12(10):588-96. PubMed ID: 26149486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-Related Aspects of Biomarkers in Cardiac Disease.
    Mingels AMA; Kimenai DM
    Adv Exp Med Biol; 2018; 1065():545-564. PubMed ID: 30051406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and diagnostics in heart failure.
    Gaggin HK; Januzzi JL
    Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.
    Berezin AE
    J Circ Biomark; 2016; 5():6. PubMed ID: 28936254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.
    Nymo SH; Aukrust P; Kjekshus J; McMurray JJ; Cleland JG; Wikstrand J; Muntendam P; Wienhues-Thelen U; Latini R; Askevold ET; Gravning J; Dahl CP; Broch K; Yndestad A; Gullestad L; Ueland T;
    JACC Heart Fail; 2017 Apr; 5(4):256-264. PubMed ID: 28359413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST2 pathogenetic profile in ambulatory heart failure patients.
    Bayes-Genis A; Januzzi JL; Gaggin HK; de Antonio M; Motiwala SR; Zamora E; Galán A; Domingo M; Urrutia A; Lupón J
    J Card Fail; 2015 Apr; 21(4):355-61. PubMed ID: 25451702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel heart failure biomarkers: why do we fail to exploit their potential?
    Piek A; Du W; de Boer RA; Silljé HHW
    Crit Rev Clin Lab Sci; 2018 Jun; 55(4):246-263. PubMed ID: 29663841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in heart failure: the past, current and future.
    Sarhene M; Wang Y; Wei J; Huang Y; Li M; Li L; Acheampong E; Zhengcan Z; Xiaoyan Q; Yunsheng X; Jingyuan M; Xiumei G; Guanwei F
    Heart Fail Rev; 2019 Nov; 24(6):867-903. PubMed ID: 31183637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and heart disease.
    Sun RR; Lu L; Liu M; Cao Y; Li XC; Liu H; Wang J; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2927-35. PubMed ID: 25339488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for heart failure: small molecules with high clinical relevance.
    Magnussen C; Blankenberg S
    J Intern Med; 2018 Jun; 283(6):530-543. PubMed ID: 29682806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ST2 and patient prognosis in chronic heart failure.
    Bayes-Genis A; Zhang Y; Ky B
    Am J Cardiol; 2015 Apr; 115(7 Suppl):64B-9B. PubMed ID: 25665758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
    Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble ST2 and galectin-3 in heart failure.
    Shah RV; Januzzi JL
    Clin Lab Med; 2014 Mar; 34(1):87-97, vi-vii. PubMed ID: 24507789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimarker testing with ST2 in chronic heart failure.
    Bayes-Genis A; Richards AM; Maisel AS; Mueller C; Ky B
    Am J Cardiol; 2015 Apr; 115(7 Suppl):76B-80B. PubMed ID: 25697916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble ST2 in heart failure.
    Dieplinger B; Mueller T
    Clin Chim Acta; 2015 Mar; 443():57-70. PubMed ID: 25269091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.